Hoechst Japan Limited

Koichi Shudo

Hoechst Aktiengesellschaft

Aventis Pharma S.a.

Hoechst Marion Roussel

Mizuho Inazu

Kazuyuki Kitamura

Tsutomu Inoue

Tatsuo Sugioka

Hideyuki Tanaka

Robert S McDowell

Volkmar Wehner

Thomas Gadek

Jochen Knolle

Christoph Naumann

Hans-Ulrich Stilz

Osamu Komiyama

Katsuhiro Yoshikawa

Roland Baron

Hans-Jochen Lang

Hiroshi Kitagawa

Denis Carniato

Heinrich Christian Englert

Masakazu Katoh

Ryoichi Satoh

Agents for promoting bone formation

There are described compounds of the formula I ##STR1## in which R.sup.1 is (C.sub.1 -C.sub.10)-alkyl, (C.sub.1 -C.sub.8)-alkanoyl, (C.sub.6 -C.sub.10)-aryl or Het, each of which can be substituted by halogen, --OH, --NH.sub.2, --NH--CO--R.sup.7, --O--CO--R.sup.7 and --N--(R.sup.8).sub.2 where R.sup.7 =(C.sub.1 -C.sub.6)-alkyl and R.sup.8, independently of one another, is hydrogen or (C.sub.1 -C.sub.2)-alkyl or in which R.sup.1 is the radical of the formula II ##STR2## in which n is an integer from 3 to 10, m is zero to 3, R.sup.6, independently of one another, is (C.sub.1 -C.sub.6)-alkyl which is optionally substituted by halogen or --NH--CO--R.sup.7, where R.sup.7 =(C.sub.1 -C.sub.6)-alkyl, and X is absent or is (C.sub.1 -C.sub.10)-alkyl, and R.sup.2, R.sup.3, R.sup.4 or R.sup.5, independently of one another, are hydrogen, (C.sub.1 -C.sub.5) -alkyl, lithium, sodium, potassium or Si(R), where R=(C.sub.1 -C.sub.5)-alkyl, and their physiologically tolerable salts, a process for preparation of these compounds of the formula I and their use as pharmaceuticals in the prophylaxis and treatment of osteoporosis and hypercalcemia.

Imidobisphosphoric acids, and use thereof

An anti-osteopathic composition comprising as an active ingredient a compound represented by the following formula (I), (II) or (Ill): ##STR1## which is useful for therapeutic and prophylactic treatment of osteopathia such as osteoporosis and bone fracture.

Anti-osteopathic composition

Imidobisphosphoric acids, process for their preparation, and use thereof. There are described compounds of the formula I ##STR1## in which R.sup.1 is (C.sub.1 -C.sub.10)-alkyl, (C.sub.1 -C.sub.8)-alkanoyl, (C.sub.6 -C.sub.10)-aryl or Het, each of which can be substituted by halogen, --OH, --NH.sub.2, --NH--CO--R.sup.7, --O--CO--R.sup.7 and --N--(R.sup.8).sub.2 where R.sup.7 =(C.sub.1 -C.sub.6)-alkyl and R.sup.8, independently of one another, is hydrogen or (C.sub.1 -C.sub.4)-alkyl or in which R.sup.1 is the radical of the formula II ##STR2## in which n is an integer from 3 to 10, m is zero to 3, R.sup.6, independently of one another, is (C.sub.1 -C.sub.6)-alkyl which is optionally substituted by halogen or --NH--CO--R.sup.7, where R.sup.7 =(C.sub.1 -C.sub.6)-alkyl, and X is absent or is (C.sub.1 -C.sub.10)-alkyl, and R.sup.2, R.sup.3, R.sup.4 or R.sup.5, independently of one another, are hydrogen, (C.sub.1 -C.sub.5)-alkyl, lithium, sodium, potassium or Si(R), where R=(C.sub.1 -C.sub.5) -alkyl, and their physiologically tolerable salts, a process for preparation of these compounds of the formula I and their use as pharmaceuticals in the prophylaxis and treatment of osteoporosis and hypercalcemia.

Imidobisphosphoric acids, and use therefor

An anti-osteopathic composition comprising as an active ingredient a compound represented by the following formula (I), (II) or (III): ##STR1## which is useful for therapeutic and prophylactic treatment of osteopathia such as osteoporosis and bone fracture.

Treatment of osteopathic comprising administering as an active ingredient a compound represented by the following formula (I), (II) or (III): ##STR1##

Method of treating bone disease with pyridine, carboxamide and

A compound represented by the general formula: ##STR1## wherein A-O-denotes a residue of a compound having an estrogenic activity; R.sub.1 denotes H or a C.sub.1 -C.sub.6 alkyl group; X denotes a single bond, a C.sub.1 -C.sub.10 alkylene group or a group of the formula ##STR2## wherein R.sub.2 denotes H or a C.sub.1 -C.sub.5 alkyl group; Z denotes a nitro group or a halogen; n is an integer of 3 to 12; k is an integer of 1 to 5; L is an integer of 0 to 5; and q is an integer of 1 to 3,

Bisphosphonate derivative

Pharmaceutical compositions for the inhibition of bone resorption comprising a pharmaceutical carrier and a therapeutically effective amount of a benzopyran derivative represented by the general formula (I) ##STR1## wherein the broken-lined bond denotes an optional double bond, R.sub.1 denotes a hydrogen atom or a hydroxyl group, R.sub.2 denotes a cyano group, a phenylsulfonyl group or a halogen-substituted methoxyl group, and R.sub.3 denotes a group having the formula ##STR2## Since they inhibit bone resorption, they are useful for the treatment and prevention of diseases associated with bone metabolism.

Pharmaceutical composition of benzopyranes for the inhibition of bone

Growing community of inventors

Iruma, Japan

Mizuho Inazu